keyword
MENU ▼
Read by QxMD icon Read
search

Oritavancin

keyword
https://www.readbyqxmd.com/read/27904526/new-agents-approved-for-treatment-of-acute-staphylococcal-skin-infections
#1
Jan Tatarkiewicz, Anna Staniszewska, Magdalena Bujalska-Zadrożny
Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains. This review covers three new anti-MRSA antibiotics that have been recently approved by the FDA: dalbavancin, oritavancin, and tedizolid. The mechanism of action, indications, antibacterial activity profile, microbial resistance, pharmacokinetics, clinical efficacy, adverse effects, interactions as well as available formulations and administration of each of these new antibiotics are described...
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27890418/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-methicillin-susceptible-and-methicillin-resistant-staphylococcus-aureus
#2
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n=15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S...
November 12, 2016: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#3
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27856721/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-vancomycin-susceptible-and-resistant-enterococci
#4
Debora Sweeney, Audrey Stoneburner, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
No abstract text is available yet for this article.
November 17, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27829328/use-of-oritavancin-novel-new-lipoglycopeptide-in-the-treatment-of-prosthetic-joint-infections-pji-a-possible-alternative-novel-approach-to-a-difficult-problem
#5
Suresh Jude Antony, Leigh G Cooper
Prosthetic joint infections (PJI) result in significant morbidity, mortality and cost to patients and the health system. Traditional treatment involves a two-staged revision and occasionally a single staged revision along with intravenous antibiotics (IV) and or oral antibiotics for several weeks to months. The use of a single staged revision along with an antibiotic which has a prolonged half life and is bactericidal would be ideal. We present 2 patients who were treated successfully with a single stage revision/antibiotic spacer and a new novel long acting lipoglycopeptide called oritavancin...
November 8, 2016: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/27721280/in-vitro-activity-of-ceftaroline-a-novel-antibiotic-against-methicillin-resistant-staphylococcus-aureus
#6
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27665522/pooled-analysis-of-single-dose-oritavancin-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-gram-positive-pathogens-including-a-large-patient-subset-with-methicillin-resistant-staphylococcus-aureus
#7
G Ralph Corey, Francis F Arhin, Matthew A Wikler, Daniel F Sahm, Barry N Kreiswirth, José R Mediavilla, Samantha Good, Claude Fiset, Hai Jiang, Greg Moeck, Heidi Kabler, Sinikka Green, William O'Riordan
Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The phase 3 studies SOLO I and SOLO II demonstrated comparable efficacy and safety of a single dose of oritavancin compared with 7-10 days of twice-daily vancomycin in adults with acute bacterial skin and skin-structure infections (ABSSSIs). The present analysis assessed clinical responses by pathogen at 48-72 h and at study days 14-24 in SOLO patients within the pooled data set...
November 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27663982/approved-glycopeptide-antibacterial-drugs-mechanism-of-action-and-resistance
#8
Daina Zeng, Dmitri Debabov, Theresa L Hartsell, Raul J Cano, Stacy Adams, Jessica A Schuyler, Ronald McMillan, John L Pace
The glycopeptide antimicrobials are a group of natural product and semisynthetic glycosylated peptides that show antibacterial activity against Gram-positive organisms through inhibition of cell-wall synthesis. This is achieved primarily through binding to the d-alanyl-d-alanine terminus of the lipid II bacterial cell-wall precursor, preventing cross-linking of the peptidoglycan layer. Vancomycin is the foundational member of the class, showing both clinical longevity and a still preferential role in the therapy of methicillin-resistant Staphylococcus aureus and of susceptible Enterococcus spp...
December 1, 2016: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/27609052/longitudinal-2001-14-analysis-of-enterococci-and-vre-causing-invasive-infections-in-european-and-us-hospitals-including-a-contemporary-2010-13-analysis-of-oritavancin-in-vitro-potency
#9
Rodrigo E Mendes, Mariana Castanheira, David J Farrell, Robert K Flamm, Helio S Sader, Ronald N Jones
OBJECTIVES: The objective of this study was to evaluate the prevalence and in vitro susceptibility of enterococci and VRE among bloodstream infections in European and US hospitals over time. METHODS: Isolates recovered from the blood of infected patients in Europe (72 996) and the USA (67 725) between 2001 and 2014 were included in the prevalence analysis. A subset (2349) collected during 2011-13 was used for the in vitro activity analysis. RESULTS: Enterococcus faecium rates increased in Europe (from 1...
December 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27598313/clinical-pathway-for-moderate-to-severe-acute-bacterial-skin-and-skin-structure-infections-from-a-us-perspective-a-roundtable-discussion
#10
John A Bosso, Anthony M Casapao, Jonathan Edwards, Kenneth Klinker, Christopher McCoy, David P Nicolau, Katherine K Perez, Andrew Marcarelli, Deeksha Dua
This article was written with the aim to establish a consensus clinical pathway for long-acting lipoglycopeptide antibiotics such as oritavancin (Orbactiv®) and dalbavancin (Dalvance®) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Seven infectious diseases pharmacy specialists from a variety of facilities across the United States (US) participated in a roundtable discussion to consider the use of newer single-dose long-acting lipoglycopeptides, and integrate them into clinical pathways for ABSSSI...
October 2016: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/27565805/erratum-to-single-dose-oritavancin-treatment-of-acute-bacterial-skin-and-skin-structure-infections-solo-trial-efficacy-by-eron-severity-and-management-setting
#11
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler, Katherine A Sulham, G Ralph Corey
No abstract text is available yet for this article.
September 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27543378/oritavancin-in-vitro-activity-against-contemporary-staphylococcus-aureus-isolates-responsible-for-invasive-community-and-healthcare-associated-infections-among-patients-in-the-united-states-2013-2014
#12
Leonard R Duncan, Helio S Sader, Robert K Flamm, Ronald N Jones, Rodrigo E Mendes
Oritavancin has been approved in the United States and European Union for the treatment of acute bacterial skin and skin structure infections caused by several Gram-positive pathogens including Staphylococcus aureus. In this study, the in vitro activity of oritavancin and comparator agents was assessed against 1008 isolates of contemporary invasive community- or healthcare-associated S. aureus (790 and 218 isolates, respectively). All sampled contemporary (2013-2014) S. aureus isolates were susceptible at ≤0...
November 2016: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27401574/evaluation-of-antibiotics-active-against-methicillin-resistant-staphylococcus-aureus-based-on-activity-in-an-established-biofilm
#13
Daniel G Meeker, Karen E Beenken, Weston B Mills, Allister J Loughran, Horace J Spencer, William B Lynn, Mark S Smeltzer
We used in vitro and in vivo models of catheter-associated biofilm formation to compare the relative activity of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) in the specific context of an established biofilm. The results demonstrated that, under in vitro conditions, daptomycin and ceftaroline exhibited comparable activity relative to each other and greater activity than vancomycin, telavancin, oritavancin, dalbavancin, or tigecycline. This was true when assessed using established biofilms formed by the USA300 methicillin-resistant strain LAC and the USA200 methicillin-sensitive strain UAMS-1...
October 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27370913/single-dose-oritavancin-treatment-of-acute-bacterial-skin-and-skin-structure-infections-solo-trial-efficacy-by-eron-severity-and-management-setting
#14
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler, Katherine A Sulham, G Ralph Corey
INTRODUCTION: Introduction of new antibiotics enabling single-dose administration, such as oritavancin may significantly impact site of care decisions for patients with acute bacterial skin and skin structure infections (ABSSSI). This analysis compared the efficacy of single-dose oritavancin with multiple-dose vancomycin in patients categorized according to disease severity via modified Eron classification and management setting. METHODS: SOLO I and II were phase 3 studies evaluating single-dose oritavancin versus 7-10 days of vancomycin for treatment of ABSSSI...
September 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27283729/early-clinical-assessment-of-response-to-treatment-of-skin-and-soft-tissue-infections-how-can-it-help-clinicians-perspectives-from-europe
#15
REVIEW
Dilip Nathwani, Matthew Dryden, Javier Garau
Skin and soft-tissue infections (SSTIs) are a common indication for antibiotic use in Europe and are associated with considerable morbidity. Treatment of SSTIs, occasionally complicated by infection with meticillin-resistant Staphylococcus aureus, can be resource intensive and lead to high healthcare costs. For patients treated in an inpatient setting, once the acute infection has been controlled, a patient may be discharged on suitable oral antibiotic therapy or outpatient parenteral antibiotic therapy. The recently confirmed efficacy of single-dose (e...
August 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27239977/progress-in-the-fight-against-multidrug-resistant-bacteria-a-review-of-u-s-food-and-drug-administration-approved-antibiotics-2010-2015
#16
Dalia Deak, Kevin Outterson, John H Powers, Aaron S Kesselheim
A weak antibiotic pipeline and the increase in drug-resistant pathogens have led to calls for more new antibiotics. Eight new antibiotics were approved by the U.S. Food and Drug Administration (FDA) between January 2010 and December 2015: ceftaroline, fidaxomicin, bedaquiline, dalbavancin, tedizolid, oritavancin, ceftolozane-tazobactam, and ceftazidime-avibactam. This study evaluates the development course and pivotal trials of these antibiotics for their innovativeness, development process, documented patient outcomes, and cost...
September 6, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27235621/new-approaches-to-antibiotic-use-and-review-of-recently-approved-antimicrobial-agents
#17
REVIEW
Andrew W Hahn, Rupali Jain, David H Spach
Antimicrobial drug-resistance continues to force adaptation in our clinical practice. We explore new evidence regarding adjunctive antibiotic therapy for skin and soft tissue abscesses as well as duration of therapy for intra-abdominal abscesses. As new evidence refines optimal practice, it is essential to support clinicians in adopting practice patterns concordant with evidence-based guidelines. We review a simple approach that can 'nudge' clinicians towards concordant practices. Finally, the use of novel antimicrobials will play an increasingly important role in contemporary therapy...
July 2016: Medical Clinics of North America
https://www.readbyqxmd.com/read/27231802/use-of-oritavancin-in-moderate-to-severe-absssi-patients-requiring-iv-antibiotics-a-u-s-payer-budget-impact-analysis
#18
Ivar S Jensen, Elizabeth Wu, Weihong Fan, Thomas P Lodise, David P Nicolau, Scott Dufour, Philip L Cyr, Katherine A Sulham
BACKGROUND: It is estimated that acute bacterial skin and skin structure infections (ABSSSI) account for nearly 10% of hospital admissions and 3.4-3.8 million emergency department visits per year in the United States. Analyses of hospital discharge records indicate 74% of ABSSSI admissions involve empiric treatment with methicillin-resistant Staphylococcus aureus (MRSA) active antibiotics. Analysis has shown that payer costs could be reduced if moderate-to-severe ABSSSI patients were treated to a greater extent in the observational unit followed by discharge to outpatient parenteral antibiotic therapy (OPAT)...
June 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27169303/new-gram-positive-agents-to-treat-acute-bacterial-skin-and-skin-structure-infections
#19
Rosanna Li, Michael D Nailor
The FDA guidance published in 2013 provided requirements for conducting ABSSSI trials. In 2014, dalbavancin, oritavancin, and tedizolid were introduced into the market after phase III noninferiority clinical trials against vancomycin (for the lipoglycopeptides) and linezolid (for tedizolid), demonstrating clinical efficacy for the treatment of ABSSSI. Great interest exists for these agents because of the postulated financial impact. Due to favorable pharmacokinetics which allow for less frequent medication administration and shorter treatment durations, these agents may prove to reduce hospital admissions and length of stay...
March 2016: Connecticut Medicine
https://www.readbyqxmd.com/read/27161039/oritavancin-a-long-acting-antibacterial-lipoglycopeptide
#20
Achim J Kaasch, Harald Seifert
Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. Multiple mechanisms of action lead to a broad activity against Gram-positive bacteria, such as staphylococci, streptococci and enterococci, including methicillin-resistant Staphylococcus aureus. Its long terminal half-life allows for single-dose treatment of acute bacterial skin and skin structure infections. Oritavancin was found to be safe and effective in treating acute bacterial skin and skin structure infections in adults and it is currently approved in the USA and in Europe for this indication...
July 2016: Future Microbiology
keyword
keyword
30796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"